prikaz prve stranice dokumenta Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia
  Download
PDF 852.89 KB
Scientific paper - Original scientific paper
Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia
Leukemia & Lymphoma, 61 (2020), 4; 934-939. https://doi.org/10.1080/10428194.2019.1702182
Pejša, Vlatko; Lucijanić, Marko; Vrkljan Vuk, Anamarija; Štoos-Veić, Tajana; Jakšić, Ozren; Jonjić, Željko; Piršić, Mario; Prka, Željko; Ivić, Marija; Fazlić Džankić, Amina; Mitrović, Zdravko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Pejša, V., Lucijanić, M., Vrkljan Vuk, A., Štoos Veić, T., Jakšić, O., Jonjić, Ž. ... Mitrović, Z. (2020). Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma, 61. (4), 934-939. doi: 10.1080/10428194.2019.1702182

Pejša, Vlatko, et al. "Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia." Leukemia & Lymphoma, vol. 61, no. 4, 2020, pp. 934-939. https://doi.org/10.1080/10428194.2019.1702182

Pejša, Vlatko, Marko Lucijanić, Anamarija Vrkljan Vuk, Tajana Štoos Veić, Ozren Jakšić, Željko Jonjić, Mario Piršić, et al. "Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia." Leukemia & Lymphoma 61, no. 4 (2020): 934-939. https://doi.org/10.1080/10428194.2019.1702182

Pejša, V., et al. (2020) 'Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia', Leukemia & Lymphoma, 61(4), pp. 934-939. doi: 10.1080/10428194.2019.1702182

Pejša V, Lucijanić M, Vrkljan Vuk A, Štoos Veić T, Jakšić O, Jonjić Ž, and sur.. Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma [Internet]. 2020 April [cited 2024 November 22];61(4):934-939. doi: 10.1080/10428194.2019.1702182

V. Pejša, et al., "Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia", Leukemia & Lymphoma, vol. 61, no. 4, pp. 934-939, April 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:272145. [Accessed: 22 November 2024]

Metadata
Title (english)Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia
AuthorVlatko Pejša
AuthorMarko Lucijanić
AuthorAnamarija Vrkljan Vuk
AuthorTajana Štoos-Veić
AuthorOzren Jakšić
AuthorŽeljko Jonjić
AuthorMario Piršić
AuthorŽeljko Prka
AuthorMarija Ivić
AuthorAmina Fazlić Džankić
AuthorZdravko Mitrović
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
First obinutuzumab application is associated with infusion related reactions (IRRs) that may discourage further continuation of the drug. During our clinical practice we have observed that chronic lymphocytic leukemia (CLL) patients with autoimmune hemolytic anemia (AIHA) prolongedly receiving corticosteroids do not develop obinutuzumab IRRs. Therefore, we decided to apply prolonged corticosteroid premedication with methylprednisolone in dose 1-1.5 mg/kg for ≥7 days to all further obinutuzumab candidates. Here we present non-randomized comparison of 28 consecutive previously untreated CLL patients receiving prolonged corticosteroid premedication (15 patients) or standard premedication (13 patients) prior to the first obinutuzumab infusion. Prolonged corticosteroid premedication resulted in significant reduction of all-grade (20% vs 61.5%; p = .025) and grade III (0% vs 23.1%; p = .049) obinutuzumab IRRs. Prolonged corticosteroid premedication did not significantly affect occurrence of infective complications. Patients with CLL and AIHA receiving obinutuzumab showed continuous and stable increase in hemoglobin levels concomitantly with decrease in parameters of hemolysis.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleLeukemia & Lymphoma
Numberingvol. 61, no. 4, pp. 934-939
p-ISSN1042-8194
e-ISSN1029-2403
DOIhttps://doi.org/10.1080/10428194.2019.1702182
URN:NBNurn:nbn:hr:105:272145
Publication2020-04
Document URLhttps://www.tandfonline.com/doi/full/10.1080/10428194.2019.1702182
Type of resourceText
Access conditionsOpen access
Embargo expiration date: 2021-04-30
Terms of useLicence In copyright icon
Created on2020-12-10 09:22:37